References:
- Cancer Facts and Statistics - (http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-026238.pdf)
- Carlos J, Mario R, Ellen S, McGee D, et al. (2013) Physical Activity and Prostate Cancer Mortality in Puerto Rican Men, Journal of Physical Activity & Men; 5(6): 918 – 929.
- Gathirua WG & Zhang J (2014) Dietary factors and risk for advanced prostate cancer. Eur J Cancer Prev; 23(2):96-109.
- Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, et al. (2010) Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA; 304(21):2373-80.
- Longest Prostate Cancer Active Surveillance Study Promising - (http://www.medscape.com/viewarticle/823590)
- Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, et al. (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol; 16(2):152-60.
- The National Association of Proton Therapy (2015) Prostate Cancer Treatment May Be Better Than "Watchful Waiting" Option. [Online] Available at: Prostate Cancer Treatment May Be Better Than "Watchful Waiting" Option
- Wolf AM, Wender RC, Etzioni RB, Thompson IM, et al. (2010) American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin; 60(2):70-98.
Editor: Dr. Sunil Shroff
Technically Checked by: Lingaraj
